Levi & Korsinsky, LLP
Search documents
LEVI & KORSINSKY, LLP INVESTIGATING ALLEGED CLINICAL TRIAL DESIGN DEFICIENCIES AT VISTAGEN THERAPEUTICS -- CLASS ACTION FILED
Prnewswire· 2026-02-25 14:00
NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Shareholder rights firm Levi & Korsinsky, LLP is investigating potential securities law violations by Vistagen Therapeutics, Inc. (NASDAQ: VTGN) and reminds investors of the March 16, 2026 deadline to seek lead plaintiff status. THE INVESTIGATION: The firm is examining whether Vistagen and certain officers made false or misleading statements during the period from April 1, 2024 through December 16, 2025. ...
Class Action Filed Against Fermi Inc. (FRMI) - March 6, 2026 Deadline to Join - Contact Levi & Korsinsky
Prnewswire· 2026-02-25 14:00
Class Action Filed Against Fermi Inc. (FRMI) - March 6, 2026 Deadline to Join - Contact Levi & Korsinsky [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fermi Inc. ("Fermi Inc." or the "Company") (NASDAQ: FRMI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fermi Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and e ...
Shareholders of Bath & Body Works, Inc. Should Contact Levi & Korsinsky Before March 13, 2026 to Discuss Your Rights - BBWI
Prnewswire· 2026-02-25 14:00
Shareholders of Bath & Body Works, Inc. Should Contact Levi & Korsinsky Before March 13, 2026 to Discuss Your Rights - BBWI [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Bath & Body Works, Inc. ("Bath & Body Works, Inc." or the "Company") (NYSE: BBWI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Bath & Body Works, Inc. investors who were adversely affected by alleged secu ...
Levi & Korsinsky Investigates Whether Ralliant's $1.4 Billion Goodwill Write-Down Reflects Previously Undisclosed Asset Deterioration
Prnewswire· 2026-02-25 14:00
Levi & Korsinsky Investigates Whether Ralliant's $1.4 Billion Goodwill Write-Down Reflects Previously Undisclosed Asset Deterioration [Accessibility Statement] Skip Navigation(NYSE: RAL)NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ralliant Corp. (NYSE: RAL) on behalf of shareholders concerning the company's February 4, 2026 disclosure of a $1.4 billion goodwill impairment charge in connection with its fourth-quarter 2025 earnings release. The impairment represents approxima ...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 31, 2026 in Ramaco Lawsuit - METC
Prnewswire· 2026-02-25 14:00
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 31, 2026 in Ramaco Lawsuit - METC [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ramaco Resources, Inc. ("Ramaco" or the "Company") (NASDAQ: METC) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ramaco investors who were adversely affected by alleged securities fraud between July 31, 2025 and October ...
LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION
Prnewswire· 2026-02-25 14:00
LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION [Accessibility Statement] Skip NavigationTime-Sensitive: Allegations Focus on Repeated Assurances Regarding Setrusumab EfficacyRARE INVESTOR ALERT"Investors deserve transparency about material risks that could affect their investments," stated Joseph E. Levi, Esq., managing partner of Levi & Korsinsky, LLP. "The adequacy of clinical trial risk disclosures is a fundamental issue for biopharm ...
Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc.(RGNX)
Prnewswire· 2026-02-25 14:00
Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc.(RGNX) [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of REGENXBIO investors who were adversely affected by alleged securities fraud between February 9, 2022 and January 27, 202 ...
Lost Money on CoreWeave, Inc.(CRWV)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
Globenewswire· 2026-02-23 21:09
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in CoreWeave, Inc. ("CoreWeave, Inc." or the "Company") (NASDAQ: CRWV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of CoreWeave, Inc. investors who were adversely affected by alleged securities fraud between March 28, 2025 and December 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/coreweave-i ...
Levi & Korsinsky, LLP: High-Risk Merchant Concentration Practices at Center of Paysafe Securities Litigation
Globenewswire· 2026-02-23 21:08
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Paysafe Limited (NYSE: PSFE) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between March 4, 2025 and November 12, 2025. Click here to learn more about this case. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. The global digital payments industry processes trillions of dollars annually, requiring careful risk segmentation by merchant ...
Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc. (RGNX)
Globenewswire· 2026-02-23 21:07
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of REGENXBIO investors who were adversely affected by alleged securities fraud between February 9, 2022 and January 27, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/regenxbio-inc-lawsuit-s ...